ES2509892T3 - Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal - Google Patents

Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal Download PDF

Info

Publication number
ES2509892T3
ES2509892T3 ES09743658.8T ES09743658T ES2509892T3 ES 2509892 T3 ES2509892 T3 ES 2509892T3 ES 09743658 T ES09743658 T ES 09743658T ES 2509892 T3 ES2509892 T3 ES 2509892T3
Authority
ES
Spain
Prior art keywords
administration
agent
antibiotic
treatment
intestinal disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09743658.8T
Other languages
English (en)
Inventor
Lorin Johnson
William Forbes
Stephana Patton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Ltd
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2509892T3 publication Critical patent/ES2509892T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Uso de un agente de limpieza del tracto gastrointestinal (GI) limpiador y una cantidad terapéuticamente eficaz de la rifaximina para la fabricación de un medicamento para tratar la enfermedad intestinal (EI), que comprende: administrar el agente de limpieza gastrointestinal (GI) a un sujeto en que lo necesite; y administrar la cantidad terapéuticamente eficaz de rifaximina, en el que la administración del agente de limpieza gastrointestinal (GI) está dentro de entre aproximadamente 1 a aproximadamente 90 días antes de la administración de la rifaximina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29

Claims (1)

  1. imagen1
ES09743658.8T 2008-05-07 2009-05-07 Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal Active ES2509892T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5134108P 2008-05-07 2008-05-07
US51341P 2008-05-07
PCT/US2009/043138 WO2009137672A1 (en) 2008-05-07 2009-05-07 Methods of treating bowel disease by administering a bowel cleanser and an antibiotic

Publications (1)

Publication Number Publication Date
ES2509892T3 true ES2509892T3 (es) 2014-10-20

Family

ID=41265004

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09743658.8T Active ES2509892T3 (es) 2008-05-07 2009-05-07 Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal

Country Status (13)

Country Link
US (2) US20090324736A1 (es)
EP (1) EP2294012B1 (es)
JP (1) JP5752032B2 (es)
AU (1) AU2009244190B2 (es)
CA (1) CA2723752A1 (es)
DK (1) DK2294012T3 (es)
ES (1) ES2509892T3 (es)
HK (1) HK1156293A1 (es)
HR (1) HRP20140939T1 (es)
PL (1) PL2294012T3 (es)
PT (1) PT2294012E (es)
SI (1) SI2294012T1 (es)
WO (1) WO2009137672A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
KR101667534B1 (ko) 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
MY158257A (en) 2008-02-25 2016-09-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
EP2337569A4 (en) 2008-09-25 2013-04-03 Univ New York COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING THE GASTROINTESTINAL, SKIN AND NASAL MICROBIOTA
JP5756020B2 (ja) 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
RU2012126084A (ru) * 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
US8532349B2 (en) * 2010-02-02 2013-09-10 Omnivision Technologies, Inc. Encapsulated image acquisition devices having on-board data storage, and systems, kits, and methods therefor
PL3677261T3 (pl) 2010-09-23 2023-10-16 Leading BioSciences, Inc. Sposób podawania inhibitorów proteazy serynowej do żołądka
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
US8778907B2 (en) * 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
CA2875351C (en) * 2012-07-17 2021-08-31 Bayer New Zealand Limited Injectable antibiotic formulations and their methods of use
PT2895163T (pt) 2012-09-11 2019-06-14 Norgine Bv Composições compreendendo peg e ascorbato
AU2013315458A1 (en) * 2012-09-12 2015-03-05 Salix Pharmaceuticals, Inc. Methods of administering rifaximin without producing antibiotic resistance
CN105025717A (zh) * 2012-09-13 2015-11-04 萨利克斯药品公司 改善患有肝性脑病的受试者的长期生存和降低其再住院率的方法
CN108904462A (zh) 2013-03-15 2018-11-30 布伦特里实验室公司 双用途硫酸盐口服药物组合物片剂及其使用方法
US20160089363A1 (en) * 2013-04-30 2016-03-31 Thomas Julius Borody Compositions and methods for treating microbiota-related psychotropic conditions and diseases
JP2016526032A (ja) * 2013-05-17 2016-09-01 サリックス ファーマスーティカルズ，インコーポレーテッド ポジション（ｐｏｓｉｔｉｏｎ）放射断層撮影（ｐｅｔ）スキャンでリファキシミンを使用する方法
US20160120915A1 (en) * 2013-06-10 2016-05-05 New York University Methods for manipulating immune responses by altering microbiota
KR101423005B1 (ko) * 2013-10-17 2014-07-28 강윤식 장 세정용 조성물
US9387199B2 (en) * 2013-11-12 2016-07-12 University Of Virginia Patent Foundation Compositions and methods for treating clostridium infection and preventing recurrence of infection
KR102397379B1 (ko) 2014-03-25 2022-05-13 리딩 바이오사이언시즈, 인크. 자가소화의 치료용의 조성물
BR112016025481A2 (pt) 2014-04-29 2017-08-15 Colonaryconcepts Llc alimentos, sistemas, métodos e estojos para provisão de substituição de eletrólito
EP3160467B1 (en) * 2014-06-30 2021-03-10 Salix Pharmaceuticals, Inc. Combination comprising rifaximin and cyclosporine for use in the treatment of bowel diseases
AU2016226380A1 (en) 2015-03-02 2017-09-21 Colonaryconcepts Llc Compounds and methods for PEG metabolite and PEG breakdown product assays
ME03671B (me) 2015-04-02 2020-10-20 Theravance Biopharma R&D Ip Llc Kombinovani oblik doze antagonista mu opioidnog receptora i opioidni agens
KR102619907B1 (ko) * 2015-08-17 2024-01-02 서화수 가축설사 치료용 복합제 조성물
CN108778268A (zh) * 2016-01-08 2018-11-09 科罗纳里康赛普茨有限责任公司 用于治疗肝性脑病的治疗剂的基于食物的递送
US10653728B2 (en) 2016-10-17 2020-05-19 New York University Probiotic compositions for improving metabolism and immunity
AU2018211305B2 (en) * 2017-04-26 2019-07-25 Sandoz Ag Oral dosage form comprising rifaximin in form beta
BR112020013996A2 (pt) 2018-01-11 2020-12-01 Meritage Pharma, Inc. composições de cortecosteroide estáveis
US20210000806A1 (en) * 2018-03-23 2021-01-07 Thomas Julius Borody Compositions and methods for treating inflammatory bowel disease and fusobacteria-caused or related diseases and conditions

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3363997A (en) 1958-12-22 1968-01-16 Monsanto Co Composition of matter and process
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
WO1987000754A1 (en) 1985-08-01 1987-02-12 Braintree Laboratories, Inc. Low-sodium laxative and lavage formulation
US5274001A (en) 1987-12-24 1993-12-28 Borody Thomas J Orthostatic lavage solutions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
EP1017404B1 (en) * 1997-09-26 2004-06-23 Medeva Europe Limited Pharmaceutical composition for the treatment of inflammatory bowel disease
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1487414A4 (en) * 2002-03-07 2007-12-12 Advancis Pharmaceutical Corp ANTIBIOTIC COMPOSITION
MXPA05002033A (es) * 2002-08-26 2005-10-19 Sla Pharma Ag Una composicion farmaceutica.
GB0224909D0 (en) * 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7687075B2 (en) * 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
WO2006102536A2 (en) 2005-03-23 2006-09-28 University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
WO2006122104A1 (en) * 2005-05-06 2006-11-16 Salix Pharmaceuticals, Inc. Polyethylene glycol colonic purgative composition
EP1996710B1 (en) * 2006-03-09 2019-08-14 Salix Pharmaceuticals, Inc. Rifaximin anti-rectal dysfunction preparation
CN101534840A (zh) * 2006-08-02 2009-09-16 萨利克斯药品公司 治疗放射性肠炎的方法
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CN101896815A (zh) * 2007-10-17 2010-11-24 萨利克斯药品有限公司 肠疾病中的新的治疗靶标
WO2019023892A1 (en) 2017-07-31 2019-02-07 SZ DJI Technology Co., Ltd. MOTION-BASED IMPRESSION CORRECTION IN POINT CLOUDS
US11960008B2 (en) 2018-05-17 2024-04-16 Cmos Sensor, Inc. Method and system for pseudo 3D mapping in robotic applications
KR102382079B1 (ko) 2020-02-11 2022-03-31 효성중공업 주식회사 에어갭 조절장치
US11963008B2 (en) 2020-11-25 2024-04-16 Truist Bank Geolocation-based notifications using relationships in separate systems

Also Published As

Publication number Publication date
JP5752032B2 (ja) 2015-07-22
US20130164384A1 (en) 2013-06-27
US20090324736A1 (en) 2009-12-31
DK2294012T3 (da) 2014-10-06
JP2011519952A (ja) 2011-07-14
HRP20140939T1 (hr) 2014-11-21
HK1156293A1 (en) 2012-06-08
WO2009137672A1 (en) 2009-11-12
EP2294012A4 (en) 2011-10-26
EP2294012B1 (en) 2014-07-09
PL2294012T3 (pl) 2014-12-31
AU2009244190B2 (en) 2016-02-25
SI2294012T1 (sl) 2014-11-28
EP2294012A1 (en) 2011-03-16
PT2294012E (pt) 2014-10-15
AU2009244190A1 (en) 2009-11-12
CA2723752A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
ES2509892T3 (es) Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal
ES2611483T3 (es) Agente terapéutico para enfermedad inflamatoria intestinal
CL2021000622A1 (es) Uso de niclosamida para la preparación de un medicamento para el tratamiento de colitis autoinmune, una enfermedad inflamatoria intestinal, colitis autoinmune iatrogénica, divisional de la solicitud de patente nº 559-2018.
ES2526648T3 (es) Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
EP2248519A3 (en) Non-mucoadhesive film dosage forms
CL2012000794A1 (es) Composicion farmaceutica solida de desintegracion oral que comprende 20 mg o menos de un un corticoesteroide y un desintegrador; tableta que se desintegra oralmente; y su uso en el tratamiento de una afeccion inflamatoria del tracto gastrointestinal como inflamacion del esofago, glosis, epiglotis, amigdalas, orofaringea, entre otras.
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CL2007002526A1 (es) Un medicamento que comprende, separado o juntos: a) una sal de glicopirronio; b) un agonista del adreno-receptor beta-2 seleccionado de salmeterol y formoterol; y c) un corticosteroide; kit farmaceutico; y uso en el tratamiento de una enfermedad infl
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
AR057876A1 (es) Tratamiento de pacientes con enfermedad renal cronica (erc) utilizando compuestos de la invencion
AR059357A1 (es) Formulaciones farmaceuticas
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
ES2559238T3 (es) Agente para reducir el peso de la grasa visceral
ECSP077843A (es) Tratamiento o prevención del prurito